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Abstract
Cholemic nephropathy represents a spectrum of renal injury, from proximal tubulopathy to intrarenal bile cast formation, found 
in patients with severe liver dysfunction. It is caused by hyperbilirubinemia, usually in jaundiced patients. Acute kidney injury 
is one of the most important complications in patients with end-stage liver disease. The relationship between liver disease and 
renal impairment, especially the effect of hyperbilirubinemia on renal tissue and renal function, has not been fully elucidated. 
These considerations deem necessary for nephrologists, when performing a clinical evaluation of patients with liver diseases, for 
the implementation of an integrated medical approach. This review focuses on the current knowledge on cholemic nephropathy 
with emphasis on the role of hyperbilirubinemia on renal impairment. The treatment strategies and outcome are also discussed.
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Introduction
Cholemic nephropathy (CN) is the clinical manifestation of 
hyperbilirubinemia that encompasses acute kidney injury 
(AKI) with characteristic histological changes in the distal 
segment of the nephron and intraluminal casts in jaundiced 
patients (1). Since the pioneer studies of Hecher and Schro-
eder, it has been known that impairment of kidney function 
is a common event in the clinical course of cirrhosis, and 
it is associated with poor prognosis (2, 3). An important 
non-vasomotor mechanism of AKI in cirrhosis is the neph-
rotoxicity of bilirubin and bile acids (4). Nephrologists are 
frequently asked to evaluate patients with liver disease- 
associated kidney disease, and the spectrum can include both 
acute and chronic kidney diseases. Kidney disorders occur 
in up to 25% of patients with liver disease (5). An under-
standing of the kidney–liver interaction is essential for the 
implementation of an integrated medical approach. Herein 
we present our current understanding of CN, the effect of 
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hyperbilirubinemia on renal dysfunction, and the treatment 
strategies, although mostly experimental, for the manage-
ment of CN.
Hyperbilirubinemia
Bilirubin is a metabolite of ferroprotoporphyrin IX (heme), 
a potentially toxic metabolite, for which the body has de-
veloped detoxification and disposition mechanisms. Eighty 
percent of bilirubin comes from the breakdown of the he-
moglobin of senescent red blood cells in the reticuloendo-
thelial system and other erythroid cells destroyed in the bone 
marrow. The remaining 20% originates from the turnover of 
heme-containing proteins from other tissues like liver and 
muscles, and sources such as myoglobin, cytochromes, cat-
alase, peroxidase, and tryptophan pyrrolase. Kupffer cells in 
the liver take up the heme where the enzyme heme oxygenase 
acts on them liberating the chelated iron; this reaction leads 
the formation of the green pigment, biliverdin. Biliverdin is 
acted on by a nicotinamide adenine dinucleotide phosphate 
(NADPH)-dependent enzyme, biliverdin reductase, releasing 
an orange–yellow pigment known as bilirubin. Bilirubin is 
insoluble in aqueous solution and is carried in circulation 
bound to albumin and transported throughout the body (6).
Hyperbilirubinemia can be the result of disorders  that lead 
to excessive bilirubin production (hemolysis), or  a decrease 
in  bilirubin clearance (hepatic or intestinal), or a combina-
tion of the two (7). Hyperbilirubinemia in adult patients can 
be the result of many benign or life-threatening disorders. 
The causes could be prehepatic, intrahepatic, or posthepatic. 
Prehepatic causes include hemolysis and hematoma resorp-
tion, leading to an increase in unconjugated bilirubin levels. 
Intrahepatic disorders can generate either unconjugated or 
conjugated hyperbilirubinemia. Causes of conjugated hy-
perbilirubinemia include (i) hepatocellular diseases like viral 
infections, chronic alcohol consumption, and autoimmune 
disorders; (ii) drug toxicity; (iii) pregnancy; (iv) parenteral 
nutrition; (v) sarcoidosis; (vi) Dubin–Johnson syndrome; 
(vii) Rotor´s syndrome; (viii) primary biliary cirrhosis; and 
(ix) primary sclerosing cholangitis. Posthepatic or extrahe-
patic disorders that elevate conjugated bilirubin can be either 
intrinsic or extrinsic to the ductal system—intrinsic factors 
include gallstones, surgical strictures, infections, intrahepatic 
malignancy, and cholangiocarcinoma, while extrinsic factors 
include extrahepatic malignancy and pancreatitis (8). Pa-
tients with high levels of unconjugated bilirubin are at risk of 
developing bilirubin encephalopathy (kernicterus). The ad-
verse effects of bilirubin could be the result of inhibition of 
DNA synthesis, uncoupling oxidative phosphorylation, and 
inhibition of adenosine triphosphatase (ATPase) activity of 
brain mitochondria. Furthermore, bilirubin-mediated inhibi-
tion of some enzyme systems, RNA and protein synthesis in 
the brain and liver, and modification of carbohydrate metab-
olism in the brain contribute to its toxicity. The abnormal 
accumulation of bilirubin in plasma and tissues lead to a yel-
low discoloration of tissues known as icterus or jaundice (9).
AKI in cirrhosis patients in the context 
of hyperbilirubinemia
AKI that occurs in patients with cirrhosis due to severe hy-
poperfusion and impairment in the systemic arterial circula-
tion has been known as hepatorenal syndrome (HRS) (10). 
In addition, impairment of kidney function can be the re-
sult of a variety of other causes, particularly volume deple-
tion, bacterial infections, nephrotoxic agents, chronic kidney 
disease, intratubular deposition of bilirubin, or a combina-
tion thereof (11–14). Bilirubin can cause adverse effects on 
kidney cells. A study using cortical slices of kidney showed 
that bilirubin was internalized by renal epithelial cells via 
the organic anion transport system, leading to the inhibition 
of  adenosine triphosphate (ATP) production,  induction of 
mitochondrial structural defects, alteration of membrane 
permeability,  and modification of  electrolyte content and 
cell volume (4). The clinical picture to distinguish CN from 
HRS is that, in HRS, the following alterations are usually 
present: altered hemodynamic function characterized by pe-
ripheral vasodilation and renal vasoconstriction, and tubular 
dysfunction with increased water and sodium reabsorption. 
In contrast, the above pathophysiological mechanisms are 
absent or rarely present in CN.
Previous studies on cirrhosis in which impairment of kid-
ney function was diagnosed with criteria other than AKI un-
derscore the importance of kidney function in determining 
prognosis in cirrhosis (15, 16). One of the problems is the strat-
ification of AKI by urinary thresholds; these patients may have 
an increased urine output because of diuretic treatment. Thus, 
urine collection is often inaccurate in clinical practice and the 
use of kinetic changes in serum creatinine (sCr) has now be-
come the key for AKI diagnosis in cirrhosis. However, it should 
be noted that the use of sCr in patients with cirrhosis is affected 
by decreased formation of creatinine from creatine in muscles 
secondary to muscle wasting, increased renal tubular secretion 
of creatinine, increased volume  distribution that could dilute 
sCr, and interference of elevated serum bilirubin with assays of 
sCr (17, 18). Because of the negatively charged reactant, bili-
rubin interferes with creatinine/picrate reaction (18). Watkins 
et al. were the first to report the considerable negative interfer-
ence on the part of bilirubin; they found, comparing the Auto-
matic Clinical Analyzer (ACA) and end point Technicon SMA 
6/60 method to measure sCr, that the ACA kinetic method gave 
considerably lower results with samples that were highly jaun-
diced (19). As a consequence, measurement of sCr in patients 
with cirrhosis overestimates glomerular filtration rate (GFR) 
or kidney function. Also, in patients with cirrhosis, sCr is an 
unreliable tool in assessing kidney function owing to the low 
production rate of creatine (the precursor of creatinine) by 
the liver with reduced muscle mass (5). Cystatin C has been 
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proposed as an alternative marker to assess kidney function, 
but using cystatin C–based formulas to assess kidney function 
in cirrhotic patients also has yielded mixed results (20).
AKI is a common and serious complication in patients 
with liver disease; among the etiologies, those related to hy-
perbilirubinemia have been less explored (15) and therefore 
our knowledge is scarce. It has been overlooked in recent 
medical literature despite its frequency (21). In addition, 
the lack of kidney biopsy in patients with liver dysfunction 
makes it difficult to establish the association between liver 
and kidney disorders (4). AKI in patients with hepatic dis-
eases or cirrhosis is now defined according to the proposal of 
the Kidney Disease Improving Global Outcome (KDIGO) 
Criteria, as an increase in sCr of >0.3 mg/dL (22). AKI af-
fects almost 50% of hospitalized patients with cirrhosis and 
is associated with poor prognosis with mortality rates reach-
ing as high as 90% (23). In 2012, the International Club of 
Ascites (ICA) organized a consensus in order to reach a new 
definition of AKI in patients with cirrhosis (Table 1). In the 
new ICA criteria for the diagnosis of AKI, the use of urine 
output as one of the criteria has been removed as it does not 
apply to patients with cirrhosis. Further, two other changes 
to the KDIGO criteria were adopted: (i) an sCr within the 
last 3 months before admission is considered a baseline value 
for the diagnosis of AKI when a value within the previous 7 
days is not available and (ii) the calculation of the baseline 
sCr by the reverse application of the Modification of Diet 
in Renal Disease (MDRD) formula using an arbitrarily de-
fined normal value of GFR of 75 mL/min/1.73 m2 was not 
included (17). The main differences between these new crite-
ria and the conventional criteria in patients with cirrhosis are 
the following: (i) an absolute increase in sCr is considered; (ii) 
the threshold of sCr > 1.5 mg/dL (133 μmol/L) is abandoned; 
and (iii), a staging system of AKI based on a change in sCr 
over a slightly longer time frame, arbitrarily set at 1 week, 
to enable assessment of progression as well as regression of 
stage (modified from AKIN staging) (Table 1).
Even a minor increment in sCr in patients with cirrhosis 
is strongly associated with mortality. Fagundes et al. demon-
strated that, in cirrhotic patients, the occurrence of AKI and 
its stage were associated with 3-month survival. While there 
was no statistically significant  difference in survival rate be-
tween stages 2 and 3, when stage 1 patients were categorized 
into two groups according to the level of sCr used in the clas-
sical definition of kidney impairment (1.5 mg/dL),  those with 
sCr less than 1.5 mg/dL, had a better survival (24). In another 
study, AKI was attributed to hyperbilirubinemia based on 
the following rationale: (i) alternative diagnoses were actively 
ruled out; (ii) the onset of AKI coincided with the onset of 
severe hyperbilirubinemia; (iii) renal pathology showed large 
bile tubular casts and a marked tubular necrosis; and (iv) sCr 
dramatically decreased when bilirubin levels improved (25).
Diagnosis of cholemic nephropathy 
CN represents a spectrum of  renal injury, from proximal 
tubulopathy to intrarenal bile cast formation, found in pa-
tients with severe liver dysfunction. CN and its numerous 
synonyms (i.e., icteric nephrosis, jaundice-related nephrop-
athy, bile cast nephropathy, bile acid nephropathy) (1) have 
been reported in many liver diseases (Table 2). Essentially, 
CNcan be suspected in any disorders that increases the bil-
irubin levels. There is a strong interaction between the bile 
salts and the kidney. Elevated plasma concentrations of  bile 
salts and bilirubin, conjugated or not, putatively mediate 
nephrotoxicity. However, it seems that a total serum biliru-
bin less than 15.1 mg/dL is not enough to trigger AKI (26). 
Sitprija et al. showed that  in obstructive jaundice (OJ) due 
Table 1. Definition of AKI in patients with cirrhosis
Stage Criteria
1 Increase in sCr ≥ 0.3 mg/dL (26.5 μmol/L) or an increase in sCr ≥ 1.5-fold to 2-fold from baseline
2 Increase in sCr > 2-fold to 3-fold from baseline
3
Increase of sCr > 3-fold from baseline or sCr ≥ 4.0 mg/dL (353.6 μmol/L), with an acute increase ≥ 0.3 mg/dL (26.5 
μmol/L) or initiation of renal replacement therapy
sCr, serum creatinine.
Table 2. Disorders reported in cholemic nephropathy
Condition Disorder
Liver failure Subacute liver failure, autoimmune hepatitis, alcoholic steatohepatitis, cirrhosis
Hepatic obstruction Cholangiocarcinoma, gallstones in the bile duct, obstructive cholestasis, cholangiocellular carcinoma
Systemic diseases Hodgkin’s lymphoma, infectious mononucleosis, Falciparum malaria
Drug-induced Anabolic steroids, antibiotics, flucloxacillin
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to cholangiocarcinoma, patients with bilirubin level  >26 
mg/dL, presented with severe renal dysfunction (26). Van 
Slambrouck et al. proposed that renal abnormalities that 
accompany hyperbilirubinemia be named bile cast nephrop-
athy as the appropriate pathological term (21). Mohapatra 
et al presented microscopy findings of  centrifuged urine 
that characteristically showed bile-stained casts, leucocytes, 
and renal epithelial cells containing granular or crystalline 
bilirubin (27). There may be some clues in the urinalysis of 
patients with CN, but these findings are nonspecific and 
lacks sensitivity and specificity for diagnosis. To the best of 
our knowledge, the biomarkers used for AKI have not been 
explored in the setting of  CN. CN diagnosis relies mostly 
on kidney biopsy. It may otherwise be overlooked in these 
patient populations because of  the obvious concern of  com-
plication related to the procedure, which carries almost a 
12% risk of  significant bleeding (5). Whether a transjugular 
approach may represent a suitable and safe alternative to 
significantly reduce such risks in this difficult-to-manage 
group of  patients needs to be explored (1).
Cholemic nephropathy with dysfunctional tubular 
manifestation
Since 1930, it has been observed that patients with OJ are 
prone to kidney damage as a result of urinary excretion of 
bilirubin and bile salts. Bilirubin accumulation in tubular 
cells directly damages the mitochondria, decreasing ATPase 
activity. It also alters the hemodynamic response to angioten-
sin II and catecholamines, together with increased natriuresis 
and reduced renal flow (28). When the bilirubin levels reach 
>20 mg/dL, exceeding the binding capacity of albumin to 
bilirubin, it accumulates in mitochondria and renal tubules, 
resulting in tubular dysfunction and acute tubular necrosis in 
conjunction with intratubular bilirubin cast (28). Martinez 
et  al. demonstrated that in patients with OJ, an increase in 
lipid peroxidation products, higher levels of total bilirubin, 
and the depletion activity of superoxide dismutase in blood 
were all related to renal dysfunction. Patients with OJ showed 
a marked increase in plasma levels of oxidative stress  markers; 
higher levels in blood were predictors of renal dysfunction in 
OJ patients (29).
The hypothetical mechanisms implicated in renal impair-
ments largely come from experimental studies. In a murine 
model, Fickert et al. ligated the common bile duct and, 3 
days later, observed renal tubular epithelial lesions; at 7 days, 
there was dilation and partial, but progressive, occlusion of 
the distal and collecting tubules, followed by overexpression 
of proinflammatory cytokines, progressive interstitial nephri-
tis, and tubulointerstitial fibrosis. This model reinforces the 
hypothesis that the accumulation and consequent excessive 
urinary excretion of potentially toxic bile acids are the main 
causes of injury (30). Odell et al. in homozygous icteric rats, 
noted accumulation of bilirubin in the renal papilla (31). 
However, there are few studies that have documented the ef-
fects on kidney function of hyperbilirubinemia in humans.
Increased serum levels of bile acids or bilirubin can impair 
proximal tubular function (proximal tubulopathy), which re-
solves as the serum levels normalize (21). As proof of tubular 
dysfunctions by bilirubins, Bairaktari et al. demonstrated in 
35 patients with OJ that uricosuria and phosphaturia, imitat-
ing Fanconi syndrome, were present (32). They performed a 
noninvasive study of the renal tubular function, by evaluating 
the excretion pattern of low-molecular weight endogenous 
metabolites. On admission, patients with OJ had significantly 
lower serum uric acid and phosphate levels and higher bile acid 
concentrations compared with 40 age- and sex-matched con-
trols. Serum uric acid levels presented a negative correlation 
with total and direct bilirubin as well as fractional excretion 
of uric acid. These patients were more prone to developing 
proximal tubular dysfunction such as glucosuria, phospha-
turia, and increased excretion of alpha  (1)-microglobulin, 
decreased levels of citrate and Hippurate, and increased lev-
els of 3-hydroxybutyrate and acetate. In 12 patients, partial 
or complete remission of jaundice was followed by an im-
provement of the proximal renal tubular damage, which can 
be interpreted as transitory tubular renal dysfunction caused 
by bilirubin (32). Increased urinary sodium excretion and de-
creased free and negative water clearances were observed in 
patients with total serum bilirubin >27.0 mg/dL. These were 
further exacerbated in the presence of f  hypoalbuminemia. 
These findings suggest that bilirubin inhibits sodium chloride 
reabsorption in the thick ascending limb of Henle’s loop and 
alters Anti-diuretic hormone (ADH) function in the collect-
ing tubules, resulting in increased hydraulic conductivity and 
decreased free water clearance (26)
Cholemic nephropathy and histologic lesions of 
the renal tubules
The vast majority of histologic lesions in CN have been re-
ported in the tubular segment of the nephron (Figure 1). 
Holmes studied 68 autopsies of OJ patients and observed 
swelling of the tubular epithelium, pigmented casts, hyper-
trophy, and hyperplasia of the parietal layer of Bowman’s 
capsule in 50 (73.5%) cases (33). Van Slambprouck et al. car-
ried out a clinicopathological study in 44 jaundice patients 
and identified that biliary pigments cause obstructive and 
inflammatory renal damage, identical to myeloma or myo-
globin nephropathy (21). This study described the presence 
of tubular bile casts across the renal tubules, and the casts 
significantly correlated with higher total and direct biliru-
bin levels in serum, and a trend toward higher sCr, aspartate 
transaminase (AST), and alanine transaminase (ALT) levels. 
Most interestingly, bile casts were predominantly present in 
jaundice patients with cirrhosis, especially in those related to 
alcohol (21). Krones et al. have described the typical appear-
ance of kidneys macroscopically and microscopically (1). 
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Macroscopically, kidneys looked yellow or green due to the 
high concentration of bilirubin. Histologically, normal glom-
eruli are found with dilated tubules, obstructed by intralumi-
nal casts. With Hall (or Fouchet) histochemical stain, these 
casts appear as green to yellow casts, and with periodic-acid 
Schiff  (PAS) staining, they appear as red to dark red-colored 
casts. In Masson trichrome staining using aniline green, bile 
casts show a green color. In addition to bile casts, kidney his-
tology may show variable degrees of acute tubular injury as 
in tubular acute necrosis and intense inflammatory reaction.
Treatment and outcome
The lack of specific therapeutic options remains an import-
ant limitation for the clinical management of CN (34). As 
the liver injury resolves and renal function recovers, the bile-
stained casts in the urine decrease in frequency until they dis-
appear altogether (35, 36).
The treatment is primarily supportive; renal replacement 
therapy has no role in directly treating CN but may be insti-
tuted for other indications. The total bilirubin is also a strong 
predictor of mortality in patients with cirrhosis and kidney 
failure. In a retrospective univariate analysis, high bilirubin 
values >3.6 mg/dL were associated with 30-day mortality 
(OR 7.20, 1.55-33.56 CI) (37).
In a prospective study, Nazar et al. assessed the predictive 
factors of response to treatment with terlipressin and albumin 
in patients with type 1 HRS. One of the independent predic-
tive factors of response to therapy was baseline serum bilirubin 
levels, and the cutoff level of serum bilirubin that best predicted 
response to treatment was 10 mg/dL (area under the curve 
(AUC)  0.77; P < 0.0001; sensitivity, 89%; specificity, 61%). 
Response rates in patients with serum bilirubin <10 mg/dL or 
≥10 mg/dL were 67 and 13%, respectively (P = 0.001) (38).
Ursodeoxycholic acid (UDCA) is thought to reduce bile 
toxicity by increasing the hydrophilicity index of biliary 
bile acids, exerting an anti-apoptotic effect, and initiating 
 possible  anti-inflammatory action related to its glucocor-
ticoid receptor agonist activity (39); however, the effect of 
UDCA in CN has not been clinically proven yet. In addition, 
norursodeoxycholic acid (NorUDCA) has antilipotoxic, 
antiproliferative, antifibrotic as well as anti-inflammatory 
effects, potentially helping improve bile duct injury (40). Kro-
nes et al. explored the therapeutic efficacy and mechanisms 
of (NorUCDA) in CN in a murine model. In CBDL mice fed 
with NorUDCA, they found that NorUDCA significantly 
lowered the serum urea and uNGAL levels, resulting in less 
severe CN as demonstrated by normal urine cytology and 
significantly reduced tubulointerstitial nephritis and renal 
 fibrosis as compared to controls. Potentially, norUDCA may 
represent an option for the treatment of CN (41). Other treat-
ments aiming to reduce bilirubin levels in patients with CN, 
such as farsenoid X receptors, peroxisome proliferator-acti-
vated receptor α, pregnane X receptor, and glucocorticoid 
receptor, might be used in future studies (40).
Removing bilirubin from the circulation makes sense and 
has been previously tried by means of   extracorporeal treat-
ment. Sens et al. reported the case of  a 37-year-old male 
Figure 1. Interactions between hyperbilirubinemia and kidney. Macroscopically, the kidney may look brownish or greenish. 
In renal tubular cells, hyperbilirubinemia affects mitochondrial function, causes phosphaturia, uricosuria, and glycosuria. Hy-
perbilirubinemia also changes the tubular architecture with necrosis and apoptosis, modulates the tonicity of the afferent and 
efferent arteriole, and, through the formation of casts, it generates obstruction and tubulointerstitial inflammation.
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who presented with a sudden alteration of  his clinical status 
in the context of  the onset of  jaundice and pruritus. Labo-
ratory findings showed hyperbilirubinemia (344 mmol/L), 
mostly conjugated (260 mmol/L), and AKI. In order to de-
crease the hyperbilirubinemia and limit its nephrotoxicity, 
the patient received nine extracorporeal albumin dialysis 
(ECAD) sessions: one with molecular adsorbent recircu-
lating system (MARS) and eight with single-pass albumin 
dialysis (SPAD). The first four sessions reduced the biliru-
bin level from 480 to 172 mmol/L, and the sCr from 444 
to 248 mmol/L without requiring hemodialysis. The aim of 
ECAD was to reduce endogenous albumin-bound toxins 
accumulated during liver failure. The two methods used in 
this case report, namely the MARS and SPAD techniques, 
proved their feasibility and efficacy to reduce bilirubin levels 
in plasma to a similar extent (25).
Conclusion
CN is renal dysfunction due to hyperbilirubinemia, appear-
ing when bilirubin is greater than 20 mg/dL. Although it 
occurs frequently, it is underdiagnosed. It is obstructive and 
cytotoxic. The mechanisms of injury, although not precisely 
known, appears to involve inflammation. There is no estab-
lished therapeutic approach for its management. It seems 
plausible to explore the use of antioxidants that limit the sec-
ondary reaction of bilirubin with renal tubules, drugs that 
limit the production of bile salts, and affordable treatments 
such as extracorporeal removal of bilirubin from blood.
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